Glycemic risk factors of diabetic vascular complications: the role of glycemic variability

被引:54
作者
Zaccardi, Francesco [1 ]
Pitocco, Dario [1 ]
Ghirlanda, Giovanni [1 ]
机构
[1] Catholic Univ, Rome, Italy
关键词
glycemic variability; continuous glucose monitoring system (CGMS); indices of variability; diabetic complications; IMPAIRED GLUCOSE-TOLERANCE; MICROVASCULAR COMPLICATIONS; CARDIOVASCULAR-DISEASE; FASTING GLUCOSE; OXIDATIVE STRESS; PLASMA-GLUCOSE; MYOCARDIAL-INFARCTION; ENHANCES APOPTOSIS; PROGNOSTIC VALUE; INSULIN THERAPY;
D O I
10.1002/dmrr.938
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Achieving adequate targets relatively to all risk factors is considered a standard of care for patients with diabetes mellitus. To date, current guidelines underline the importance of the 'glucose triad' (post-prandial glucose, fasting plasma glucose and glycated haemoglobin) as the three glycemic factors that should be controlled in diabetes care; however, several literature data show that optimizing glycemic control needs achieving a control of glycemic variations. The objective of the present work is reviewing biological and clinical data supporting the role of glycemic variability, its measurement and relationship with the three other well-known glycemic risk factors and evidencing the areas that need further investigation. At last, we propose a simple model that summarizes the 'glucose triad' plus the 'new' risk factor glycemic variability (the 'Pyramid of the Risk'). Copyright (c) 2009 John Wiley & Sons, Ltd.
引用
收藏
页码:199 / 207
页数:9
相关论文
共 74 条
[1]  
Alberti KGMM, 1997, DIABETIC MED, V14, P7, DOI 10.1002/(SICI)1096-9136(199701)14:1<7::AID-DIA321>3.3.CO
[2]  
2-V
[3]  
*AM DIAB ASS, 2008, DIABETES CARE S1, V31
[4]  
[Anonymous], 1996, DIABETES, V45, P1289
[5]  
[Anonymous], 1995, DIABETES, V44, P968
[6]  
[Anonymous], 2002, DIABETES CARE, V26, P917
[7]   Is there glycemic threshold for mortality risk? [J].
Balkau, B ;
Bertrais, S ;
Ducimetiere, P ;
Eschwege, E .
DIABETES CARE, 1999, 22 (05) :696-699
[8]   QUALITY-CONTROL OF INTENSIFIED INSULIN THERAPY - HBA(1) VERSUS BLOOD-GLUCOSE [J].
BISCHOF, F ;
MEYERHOFF, C ;
PFEIFFER, EF .
HORMONE AND METABOLIC RESEARCH, 1994, 26 (12) :574-578
[9]  
Borch-Johnsen K, 1999, LANCET, V354, P617
[10]   The pathobiology of diabetic complications - A unifying mechanism [J].
Brownlee, M .
DIABETES, 2005, 54 (06) :1615-1625